stockrow
Friday 6 November 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
103.54
19.42
−15.79%
Follow HALO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.29 | 22.24 | 22.13 | 25.79 |
+8 more quarters Free account |
P/S ratio |
6.97 | 5.52 | 5.06 | 5.77 | |
P/FCF ratio |
14.18 | 11.39 | 11.44 | 12.51 | |
P/Operating CF |
48.64 | 38.10 | 42.40 | 36.82 | |
P/B ratio |
0.00 | 63.95 | 34.77 | 165.22 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.18 | 6.67 | 6.27 | 7.72 | |
EV/EBITDA |
20.49 | 15.43 | 15.27 | 19.20 | |
EV/Operating CF |
16.41 | 13.55 | 13.97 | 16.54 | |
EV/FCF |
16.64 | 13.76 | 14.17 | 16.72 | |
Quick Ratio |
3.36 | 1.99 | 2.14 | 3.30 | |
Current Ratio |
3.88 | 2.71 | 2.76 | 4.66 | |
Net Debt/EBITDA |
0.00 | 5.93 | 8.28 | (31.07) | |
Debt/Assets |
93.58% | 83.29% | 80.24% | 84.85% | |
Debt/Equity |
(58.84) | 14.95 | 9.76 | 43.89 | |
Asset Turnover |
0.63 | 0.72 | 0.62 | 0.61 | |
Operating CF/Net income |
1.05 | 1.05 | 1.20 | (1.55) | |
Capex/Depreciation |
— | (0.12) | (0.10) | (15.78) | |
Interest Coverage |
48.80 | 51.48 | 33.50 | (18.91) | |
Research and Development Expense of Revenue |
5.63% | 5.75% | 6.79% | 70.12% | |
Selling, General and Administrative Expense of Revenue |
11.81% | 11.85% | 15.36% | 17.05% | |
Intangible Assets out of Total Assets |
0.42 | 0.58 | 0.57 | 0.62 | |
Share Based Compensation of Revenue |
3.41% | 3.68% | 4.42% | 3.67% | |
Graham Net Nets |
(0.13) | (0.16) | (0.19) | (0.20) | |
Graham Number |
0.00 | 9.85 | 11.05 | 4.89 | |
Earnings Yield |
3.80% | 4.50% | 4.52% | 3.88% | |
Free Cash Flow Yield |
7.05% | 8.78% | 8.74% | 7.99% | |
Revenue per Share |
4.33 | 4.10 | 3.19 | 3.77 | |
Operating CF per Share |
2.27 | 2.05 | 1.52 | 1.83 | |
Capex per Share |
0.00 | (0.04) | (0.03) | (3.76) | |
Free Cash Flow per Share |
2.27 | 2.02 | 1.49 | (1.93) | |
Cash per Share |
9.44 | 1.97 | 2.70 | 1.19 | |
Shareholders Equity per Share |
(0.49) | 1.22 | 1.86 | 0.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.49) | 1.22 | 1.86 | 0.41 | |
Free Cash Flow |
258.27 | 236.72 | 176.34 | (231.27) | |
Working Capital |
1,370.64 | 588.59 | 639.83 | 648.12 | |
Capital Expenditures |
— | (4.17) | (3.74) | (450.30) | |
Net Current Asset Value |
(1,681.85) | (1,500.84) | (1,450.05) | (1,651.30) | |
EV/EBIT |
21.86 | 18.58 | 18.48 | 22.98 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 1.00 | |
Price to Operating Income |
18.63 | 15.37 | 14.91 | 17.20 | |
| Other line items | |||||
Average Receivables |
435.81 | 386.08 | 381.31 | 374.86 | |
Average Payables |
24.45 | 21.15 | 17.09 | 15.57 | |
Average Inventory |
159.20 | 159.32 | 160.17 | 159.17 | |
Average Assets |
2,847.29 | 2,315.65 | 2,434.63 | 2,294.40 | |
Average Common Equity |
224.34 | 238.15 | 350.95 | 206.32 |
Columns are period end dates · fundamentals updated 5 Nov 2026